Active Ingredient History

  • Now
Bosutinib (trade name Bosulif) originally synthesized by Wyeth, it is being developed by Pfizer. Bosutinib received US FDA and EU European Medicines Agency approval on September 4, 2012 and 27 March 2013 respectively for the treatment of adult patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance, or intolerance to prior therapy. Bosutinib is a synthetic quinolone derivative and dual kinase inhibitor that targets both Abl and Src kinases with potential antineoplastic activity. Unlike imatinib, bosutinib inhibits the autophosphorylation of both Abl and Src kinases, resulting in inhibition of cell growth and apoptosis. Because of the dual mechanism of action, this agent may have activity in resistant CML disease, other myeloid malignancies and solid tumors. Abl kinase is upregulated in the presence of the abnormal Bcr-abl fusion protein which is commonly associated with chronic myeloid leukemia (CML). Overexpression of specific Src kinases is also associated with the imatinib-resistant CML phenotype.   NCATS

  • Mol. Mass: 530.446
  • ALogP: 5.19
  • ChEMBL Molecule:
More Chemistry

Drug Pricing (per unit)

United States

$92.3093 - $486.1117
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methyl-1-piperazinyl)propoxy)-3-quinolinecarbonitrile | bosulif | bosulif® | bosutinib | bosutinib (as monohydrate) | bosutinib hydrate | bosutinib monohydrate | lumacaftor / ivacaftor | ski606 | ski 606 | ski-606 | tezacaftor/ivacaftor | uglysycpd2 | way-173606


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue